Zwolle Score: Can a Risk Score Decide Where STEACS Patients Should Stay?

The mortality of ST-segment elevation acute coronary syndromes (STEACS) has decreased thanks to improved reperfusion times (fibrinolysis or primary angioplasty), so that, in daily practice, there is a greater number of patients with stable acute myocardial infarction (AMI).

Score de Zwolle ¿Puede un score de riesgo decidir el lugar de estadía de los pacientes con SCACEST?

This clinical stability and a low rate of complications raise the question of whether performing triage is necessary to avoid overusing beds in cardiac intensive care units (CICUs). This is particularly relevant due to an increasing shortage of physical operating capacity in healthcare facilities—particularly in critical care units—, a phenomenon that has been exacerbated by the COVID-19 pandemic.

The Zwolle score (SDZ) was initially designed to identify probable post-angioplasty complications (percutaneous transluminal coronary angioplasty, PTCA) in patients with STEACS. It is a useful and practical score for risk stratification in this population. Its variables are Killip status at admission, TIMI flow after intervention, age, three-vessel disease, previous infarction, and the presence of myocardial ischemia lasting more than four hours.

This score had been previously validated for early discharge after PTCA for STEACS, and for patient assessment for admission to telemetry wards according to risk. Its usefulness in patients who undergo PTCA after fibrinolytic therapy administration (rescue angioplasty or facilitated angioplasty) is currently unknown.

The aim of this prospective, single-center study was to evaluate the safety of SDZ for the triage of patients with STEACS after PTCA, including subjects who received fibrinolytic therapy prior to the intervention.

Read also: Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

With previously stipulated and validated thresholds, patients with SDZ ≥4 or cardiorespiratory arrest (CRA) on admission or in the cath lab, being admitted to a CICU after the intervention, were considered high risk. Patients with SDZ ≤4, admitted to a ward with telemetry available, were low risk.

The study included 452 patients with STEACS, aged 65±12 years, 73% of whom were men. Of these, 257 experienced SDZ ≤4 (low risk) and 195 SDZ ≥4 (high risk). 

In the low-risk group, in-hospital mortality was 0.4%. Of these patients, 2% presented complications related to critical care, with an average hospitalization time of 3 days (RIC 2-3, p = 0.003). In the high-risk group, in-hospital mortality was 13%, with an average hospitalization time of 4 days (RIC 3-5), a higher rate of cardiogenic shock (34% vs. 1%), and of ventricular arrhythmia (25% vs. 2%), requiring some type of ventricular assistance during hospitalization (IABP, ECMO VA, etc.) in 4% of cases. 

Read also: Is Epinephrine Superior to Adenosine in No-REFLOW?

In the subanalysis of patients who received fibrinolytic therapy, who accounted for 16% of the total (59% were for rescue angioplasty and 41% for the facilitated strategy), the high-risk group had higher in-hospital mortality and greater probability of cardiogenic shock.

Conclusions

SDZ is a useful and practical score for risk stratification in STEACS patients. There were no data available on a population receiving fibrinolytic therapy. Low-risk patients had lower mortality and fewer events. Its application could impact clinical decision making and treatment-associated costs. Using this tool could help to improve bed distribution, thus avoiding an eventual collapse of the system.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org

References: Parr CJ, Avery L, Hiebert B, Liu S, Minhas K, Ducas J. Using the Zwolle Risk Score at Time of Coronary Angiography to Triage Patients With ST-Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention or Thrombolysis. J Am Heart Assoc. 2022 Feb 15;11(4):e024759. doi: 10.1161/JAHA.121.024759. Epub 2022 Feb 8. PMID: 35132867.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....